Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211707 | 0.92 | MEN1 (0.71) | MEN1KMT2APOLB | |
| SCHEMBL11444906 | 0.72 | POLB (0.54) | MEN1KMT2APOLB | |
| SCHEMBL6631891 | 0.69 | MEN1 (0.46) | MEN1KMT2APOLB | |
| SCHEMBL7103060 | 0.69 | POLB (0.46) | MEN1KMT2APOLB | |
| SCHEMBL7099367 | 0.69 | MEN1 (0.46) | MEN1KMT2APOLB | |
| SCHEMBL7098427 | 0.68 | MEN1 (0.46) | MEN1KMT2APOLB | |
| SCHEMBL13261902 | 0.67 | ALDH1A1 (0.51) | MEN1KMT2APOLB | |
| SCHEMBL7153122 | 0.67 | MEN1 (0.45) | MEN1KMT2APOLB | |
| SCHEMBL11445047 | 0.66 | POLB (0.63) | MEN1KMT2APOLB | |
| SCHEMBL7097929 | 0.66 | MEN1 (0.44) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931280-B1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | MEN1 2772/4885KMT2A 1881/4885POLB 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.